secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-07-22T11:10:49+00:00
Accession:  0001599298-26-000058
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit reports updated OS HR 0.76 for ivonescimab in HARMONi; consistent in western and Asian patients
--------------------------------------------------------------------------------

- Updated OS analysis from Phase III HARMONi shows HR 0.76 for full ITT population and western subgroup.
- Western patients median follow-up now 23.2 months; Asian patients locked at 32.7 months.
- Ivonescimab plus chemo continues to show acceptable safety profile; no new safety signals.
- BLA for ivonescimab in EGFR-mutated NSCLC under FDA review; PDUFA date November 14, 2026.
- Results made available to FDA; detailed data planned for presentation at upcoming medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000058/0001599298-26-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000058/smmt-20260722.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer